Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Early INB-100 results showed the potential to achieve durable remissions and improve survival in patients with complex leukemias, particularly AML.

Ziftomenib elicited positive responses in patients with NPM1-mutant acute myeloid leukemia, meeting the primary end point of the phase 2 KOMET-001 trial.